ArticleBrain and behavior2026
Prognostic Value of Elevated miR-502-3p in Patients With Post-Stroke Cognitive Impairment.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Blood-Based Biomarkers for Post-Stroke Cognitive Impairment.Current issues in molecular biology · 2026Review
- Prognostic Value of Elevated miR-502-3p in Patients With Post-Stroke Cognitive Impairment.Brain and behavior · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPost-stroke cognitive impairment (PSCI) is a common complication following a stroke. Recent findings highlight the role of miR-502-3p in both vascular and neurodegenerative diseases. However, the role in PSCI remains uncovered.
objectiveThis study emphasized the differential expression of miR-502-3p and subsequently evaluated the predictive value of miR-502-3p expression levels for PSCI. MATERIALS AND
methodsThe study subjects included 112 patients with PSCI and 161 individuals with post-stroke cognitive normality. The relative expression of miR-502-3p was calculated by qPCR, while its predictive value for PSCI was assessed via ROC curve. Pearson's correlation coefficient was utilized to analyze the correlation between serum miR-502p-3p levels and PSCI. Multivariate logistic regression was used to identify risk factors of PSCI.
resultsSerum miR-502-3p was identified as significantly elevated in the PSCI group. The area under the ROC curve was 0.850, with a sensitivity of 76.79% and a specificity of 77.64%. The miR-502-3p level was positively correlated with both NIHSS and mRS scores. In addition, a negative correlation was observed between the miR-502-3p level and MoCA score. Elevated miR-502-3p and hypertension were identified as independent risk factors for PSCI.
conclusionSignificantly elevated serum miR-502-3p was a promising biomarker for the onset of PSCI. Elevated miR-502-3p and hypertension were independent risk factors for PSCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.